Today: 17 May 2026
Browse Category

NASDAQ:XNDU 26 April 2026 - 15 May 2026

Xanadu Quantum Technologies Stock Gets Its First Public Earnings Test—and Losses Still Rule

Xanadu Quantum Technologies Stock Gets Its First Public Earnings Test—and Losses Still Rule

Xanadu Quantum Technologies reported first-quarter revenue of $2.8 million, up from $0.7 million a year earlier, but net loss widened to $20.6 million. Shares rose 1.9% to $15.13 in late U.S. trading before falling over 3% after hours. The company ended March with $272.5 million in cash and plans a $300 million at-the-market facility. Xanadu began trading on Nasdaq and TSX under XNDU on March 27.
15 May 2026
···
Xanadu Stock Faces a New Test as 2X ETF Debuts After 294 Million-Share Filing

Xanadu Stock Faces a New Test as 2X ETF Debuts After 294 Million-Share Filing

Xanadu Quantum Technologies shares dropped 6.16% to $16.31 Friday morning after a resale prospectus flagged nearly 294 million shares and Tradr ETFs launched a 2x long fund tied to the company. The firm will report first-quarter results after markets close on May 14. Radical Ventures II GP Inc. disclosed a 21.56% stake. Xanadu recently announced a chipmaking partnership with EV Group.
8 May 2026
··
Xanadu Quantum Technologies Stock Gets First Big Test as Q1 Results Date Lands

Xanadu Quantum Technologies Stock Gets First Big Test as Q1 Results Date Lands

Xanadu Quantum Technologies will report first-quarter results May 14, its first earnings since going public last month. Shares closed at $36.12 Friday, up $7.05, with 4.28 million traded. The company posted a $70.7 million net loss in 2025 and raised $302 million via a SPAC merger. Investors will watch the call for updates on spending, cash runway, and funding prospects.
1 May 2026
··
Xanadu Stock Rises After 294 Million-Share Filing: What Changes Now for XNDU

Xanadu Stock Rises After 294 Million-Share Filing: What Changes Now for XNDU

Xanadu Quantum Technologies’ U.S.-listed shares rose 7.28% to $30.95 Friday after a new registration statement signaled up to 293.7 million Class B shares could be resold by securityholders. The Toronto-based quantum computing firm, public for less than a month, reported 2025 revenue of $4.6 million and a net loss of $70.7 million. The registration statement is not yet effective.
26 April 2026
·

Stock Market Today

  • Capital One’s Strategic Shift with Discover and Brex Challenges Valuation
    May 17, 2026, 1:08 AM EDT. Capital One Financial (NYSE:COF) is undergoing a major transformation by acquiring Discover and Brex, aiming to become a technology-led "unbank" model expanding its consumer and fintech reach. While the stock trades at $187.17, around 27% below analyst targets, it faces near-term pressure with a 24.5% year-to-date decline. Investors focus on integration success, impacts on earnings, return on equity, and long-term growth amid the pivot. The company's profit margin dropped to 7.1% from 16.1%, highlighting execution risks. Market watchers will monitor price-to-earnings ratios and analyst sentiment as Capital One navigates this strategic repositioning, seeking a stronger, more resilient earnings base over time.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Go toTop